

Haleh BAGHERI - Publications 2015-2019

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juillet 2019

2019

1. **Bagheri H.** [Interest of pharmacoepidemiology for the study of anticoagulants.](#) Therapie. 2019 Apr;74(2):245-248. doi: 10.1016/j.therap.2018.09.075.
2. Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczyncha D, **Bagheri H**, Cathebras P. [Muscle Damage Due to Fusidic Acid-Statins Interaction: Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports.](#) Am J Ther. 2019 May/Jun;26(3):e375-e379. doi: 10.1097/MJT.0000000000000679.
3. Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Montastruc F, **Bagheri H**, Montastruc JL. [Are Lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.](#) Fundam Clin Pharmacol. 2019 Jun 28. doi: 10.1111/fcp.12496. [Epub ahead of print]
4. Humbert X, Fedrizzi S, Chrétien B, Sassier M, **Bagheri H**, Combret S, Drici MD, Le Bas F, Puddu PE, Alexandre J. [Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases.](#) Fundam Clin Pharmacol. 2019 Jun;33(3):296-302. doi: 10.1111/fcp.12440.
5. Montastruc JL, Montastruc F, Benevent J, Lacroix I, Durrieu G, Du Plantier JM, **Bagheri H**, Sommet A, Damase-Michel C. [Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach.](#) Therapie. 2019 Jun;74(3):445-447. doi: 10.1016/j.therap.2019.01.002.
6. Montastruc JL, Benevent J, Montastruc F, **Bagheri H**, Despas F, Lapeyre-Mestre M, Sommet A. [What is pharmacoepidemiology? Definition, methods, interest and clinical applications.](#) Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001.
7. Mouly S, Roustit M, **Bagheri H**, Perault-Pochat MC, Molimard M, Bordet R. [The French Levothyrox® crisis: We did the best we could but....](#) Therapie. 2019 Jun;74(3):431-435. doi: 10.1016/j.therap.2019.01.003.
8. Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, Nguyen TN, Nguyen DH, Nguyen TB, Montastruc JL, **Bagheri H.** [Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality Analysis.](#) Drug Saf. 2019 May;42(5):671-682. doi: 10.1007/s40264-018-0758-8.
9. Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, **Bagheri H.** [Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.](#) J Clin Pharm Ther. 2019 Feb;44(1):69-77. doi: 10.1111/jcpt.12754.
10. Nicol C, Moulis F, Bondon-Guitton E, Durrieu G, Montastruc JL, **Bagheri H.** [Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.](#) Therapie. 2019 Mar 31. pii: S0040-5957(19)30050-2. doi: 10.1016/j.therap.2019.01.008. [Epub ahead of print]

11. Petitpain N, Devos D, **Bagheri H**, Rocher F, Gouraud A, Masmoudi K, Coquerel A. [Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?](#) Fundam Clin Pharmacol. 2019 May 6. doi: 10.1111/fcp.12480. [Epub ahead of print]

2018

1. Béné J, Rousselin C, **Bagheri H**, Vial T, Gautier S, Lambert M. [Nonhemorrhagic joint disorders and vitamin K antagonists: an under-recognized adverse drug reaction?](#) Fundam Clin Pharmacol. 2018 Dec;32(6):663-668. doi: 10.1111/fcp.12380.
2. Diaz H, **Bagheri H**, Palmaro A, Rousseau V, Bourrel R, Montastruc JL, Birebent J. [Patterns of direct oral anticoagulant drug prescription in France in 2010-2013: a study in the Midi-Pyrénées area.](#) Eur J Clin Pharmacol. 2018 Jul;74(7):945-951. doi: 10.1007/s00228-018-2449-x.
3. Montastruc F, **Bagheri H**, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.](#) Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.
4. Montastruc JL, Benevent J, Montastruc F, **Bagheri H**, Despas F, Lapeyre-Mestre M, Sommet A. [What is pharmacoepidemiology? Definition, methods, interest and clinical applications.](#) Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001.
5. Nguyen KD, Bagheri B, **Bagheri H**. [Drug-induced bone loss: a major safety concern in Europe.](#) Expert Opin Drug Saf. 2018 Oct;17(10):1005-1014. doi: 10.1080/14740338.2018.1524868.
6. Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, **Bagheri H**, Olsson S. [Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country.](#) Drug Saf. 2018 Feb;41(2):151-159. doi: 10.1007/s40264-017-0598-y.
7. Petitpain N, Argouillon L, Masmoudi K, Fedrizzi S, Cottin J, Latache C, Mertes PM, Gillet P; French Network of Regional Pharmacovigilance Centres. (**Bagheri H** collaborator). [Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012.](#) Allergy. 2018 Nov;73(11):2224-2233. doi: 10.1111/all.13456.

2017

8. Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, **Bagheri H**, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. [Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People's Democratic Republic.](#) Drug Saf. 2017 Sep;40(9):809-821. doi: 10.1007/s40264-017-0544-z.
9. Couture G, Delzor F, **Bagheri H**, Micallef J, Ruysen-Witrand A, Laroche M. [First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.](#) Joint Bone Spine. 2017 Mar;84(2):213-215. doi: 10.1016/j.jbspin.2016.11.004.
10. Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, **Bagheri H**, Montastruc F, Montastruc JL. [Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase®, the WHO pharmacovigilance database.](#) Fundam Clin Pharmacol. 2017 Jun;31(3):359-366. doi: 10.1111/fcp.12264.
11. Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, **Bagheri H**. [Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France.](#) Eur J Clin Pharmacol. 2017 Apr;73(4):471-477. doi: 10.1007/s00228-016-2185-z.

12. Severino-Freire M, Lamant L, **Bagheri H**, Mazereeuw-Hautier J, Paul C. [\[Drug eruption with clomifene citrate in a bodybuilder\]](#). Ann Dermatol Venereol. 2017 Jun 20. pii: S0151-9638(17)30229-6. doi:

2016

1. **Bagheri H**, Lacroix I, Guitton E, Damase-Michel C, Montastruc JL. [Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?](#) Therapie. 2016 Apr;71(2):235-9. doi: 10.1016/j.therap.2015.09.002.
2. **Bagheri H**, Laroche ML, Montastruc JL. [Pharmacovigilance: The new challenges.](#) Therapie. 2016 Apr;71(2):121-2. doi: 10.1016/j.therap.2016.02.019.
3. Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, **Bagheri H**, Huguet F, Despas F, Pathak A, Montastruc JL. [Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.](#) Target Oncol. 2016 Aug;11(4):549-52. doi: 10.1007/s11523-016-0417-x.
4. Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, **Bagheri H**. [Risk of hormone therapy in transgender people: Literature review and data from the French Database of Pharmacovigilance.](#) Ann Endocrinol (Paris). 2016 Feb;77(1):14-21. doi: 10.1016/j.ando.2015.12.001.
5. Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, **Bagheri H**, Montastruc F. [Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study.](#) Pharmacol Res. 2016 Jun 2. pii: S1043-6618(16)30493-5. doi: 10.1016/j.phrs.2016.05.024.
6. De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, **Bagheri H**, Rascol O, Pariente A, Bégaud B, Montastruc F. [Atropinic \(Anticholinergic\) Burden in Parkinson's Disease.](#) Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595.
7. Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, **Bagheri H**, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. [\[Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits\]](#). Therapie. 2016 Oct 27. pii: S0040-5957(16)31206-9. doi: 10.1016/j.therap.2016.09.004.
8. Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, **Bagheri H**. [Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years.](#) Eur J Clin Pharmacol. 2016 May;72(5):631-9. doi: 10.1007/s00228-016-2022-4.
9. Montastruc JL, Chebane L, **Bagheri H**. [Comment on: "Drug-Induced Hyperglycaemia and Diabetes".](#) Drug Saf. 2016 May;39(5):465-6. doi: 10.1007/s40264-016-0397-x.
10. Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, **Bagheri H**. [Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database.](#) Fundam Clin Pharmacol. 2016 Apr;30(2):162-71. doi: 10.1111/fcp.12171.
11. Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, **Bagheri H**. [\[Proton pump inhibitors: Real indication or trivialized prescription?\]](#) Therapie. 2016 Dec;71(6):589-593. doi: 10.1016/j.therap.2016.05.008.

2015

1. Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, **Bagheri H**, Montastruc JL. [Adverse drug reactions to self-medication: a study in a pharmacovigilance database.](#) Fundam Clin Pharmacol. 2015 Oct;29(5):517-20. doi: 10.1111/fcp.12140.

2. Chebane L, **Bagheri H**, Hillaire-Buys D, Géniaux H, Yahoui N, Laroche ML, Cottin J, Spreux A, Mosquet B, Pecriaux C, Bellet F, Lambert A, Montastruc JL. [\[Drug-induced pancreatitis. A review of French spontaneous reports\]](#). Rev Med Interne. 2015 Sep;36(9):573-8. doi: 10.1016/j.revmed.2015.04.012.
3. Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, **Bagheri H**, Montastruc JL. [Drugs and Sleep Apneas? A review of the French Pharmacovigilance database](#). Therapie. 2015 Jul-Aug;70(4):347-50. doi: 10.2515/therapie/2014218.
4. Montastruc F, Palmaro A, **Bagheri H**, Schmitt L, Montastruc JL, Lapeyre-Mestre M. [Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase](#). Eur Neuropsychopharmacol. 2015 Oct;25(10):1556-65. doi: 10.1016/j.euroneuro.2015.07.010.
5. Montastruc F, Rouanet S, Gardette V, Rousseau V, **Bagheri H**, Montastruc JL. [\[Hospital readmission induced by adverse drug reaction: a pilot study in a post-emergency unit of a French university hospital\]](#). Rev Med Interne. 2015 Jul;36(7):450-6. doi: 10.1016/j.revmed.2014.11.016.
6. Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, Montastruc F, **Bagheri H**. [Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists \(VKA\) and direct oral anticoagulants \(DOA\)](#). Eur J Clin Pharmacol. 2015 Oct;71(10):1283-4. doi: 10.1007/s00228-015-1905-0.
7. Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, **Bagheri H**. [\[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation\]](#). Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032.
8. Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, **Bagheri H**. [Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?](#) J Clin Pharm Ther. 2015 Aug;40(4):477-9. doi: 10.1111/jcpt.12278.